Teramed Targets Contraindicated Patients For AAA Stent Graft Market Entry
This article was originally published in The Gray Sheet
Teramed's kick-off of clinical studies for the Ariba and Tributary abdominal aortic aneurysm stent graft systems indicates both the rapid pace of differentiating innovation in the AAA market and industry's continued interest in minimally invasive surgical solutions to vascular disease.
You may also be interested in...
Guidant has begun shipping its Ancure endovascular graft for treatment of abdominal aortic aneurysm, and Medtronic is expected to launch its AneuRx AAA device shortly once the company's surgeon training program is finalized. FDA simultaneously approved the two devices on Sept. 28.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.